The Diabetic Retinopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Diabetic Retinopathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued products.

GlobalData tracks 166 drugs in development for Diabetic Retinopathy by 136 companies/universities/institutes. The top development phase for Diabetic Retinopathy is preclinical with 99 drugs in that stage. The Diabetic Retinopathy pipeline has 155 drugs in development by companies and 11 by universities/ institutes. Some of the companies in the Diabetic Retinopathy pipeline products market are: Palatin Technologies, Unity Biotechnology and PharmAbcine.

The key targets in the Diabetic Retinopathy pipeline products market include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA), Vascular Endothelial Growth Factor (VEGF) , and Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF).

The key mechanisms of action in the Diabetic Retinopathy pipeline product include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor with 13 drugs in Filing rejected/Withdrawn. The Diabetic Retinopathy pipeline products include 14 routes of administration with the top ROA being Intravitreal and 16 key molecule types in the Diabetic Retinopathy pipeline products market including Small Molecule, and Monoclonal Antibody.

Diabetic Retinopathy overview

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings in the vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use.

For a complete picture of Diabetic Retinopathy’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.